Seer (SEER) Stock
Proteomics platform for drug development and diagnostics. Here's the price, business snapshot, and what's worth knowing about Seer in October 2026.
Seer Inc (SEER) develops proteomics technology intended to help researchers detect and quantify proteins at scale for biomarker discovery, drug development and diagnostics. The company sells a platform that combines proprietary consumables with instrumentation and software to analyse complex biological samples. As a small-cap business (market cap approximately $122.26M), Seer may still be in an early commercialisation phase, which can mean higher growth potential but also greater volatility and execution risk. Investors should consider revenue trends, R&D spending, cash runway and partnerships when assessing prospects. This summary provides general, educational information only and is not personal financial advice. Investments can go down as well as up; check suitability for your circumstances and consider consulting a regulated financial adviser before acting.
Seer (SEER) Stock Forecast
Analyst price target, next 12 months
$7.00
+211.1% vs today's $2.25
Price range over the last 12 months
Close to its 12-month high
Analysts covering Seer have a consensus 12-month target of $7.00, above the current price of $2.25.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 25 May 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying SEER's stock, predicting it could rise significantly in value.
Financial Health
SEER INC is showing moderate revenue and cash flow, with a reasonable gross margin.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Proteomics platform growth
Seer’s platform targets a growing demand for large-scale protein measurement in research and diagnostics, though commercial adoption can take time and vary by market.
Technology-led offering
Proprietary consumables plus instruments and software may create recurring revenue if customers scale usage, but product execution and competition matter.
Partnerships and reach
Collaborations with research groups and biopharma can validate the technology and drive sales, though regulatory and market hurdles remain.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
